Jason Richard Snape

Jason Richard Snape

Prof

Accepting PhD Students

PhD projects

Professor Snape is interested in hearing from self-funded students, students who have a scholarship, or companies who wish to pursue a PhD on topics relating to: (i) the environmental hazard and risk that pharmaceuticals, plant protection products, biocides, personal care products and household products pose to the natural environment; (ii) novel metagenomic and machine learning approaches to assess chemical persistence, biodegradability and mobility earlier in product development; (iii) the environmental dimension of antimicrobial resistance and associated mitigation measures; (iv) the environmental impact of access to healthcare and medicines in low and middle income countries; and (v) the environmental sustainability of healthcare in a climate impacted world.

Personal profile

Research interests

Over the past 25 years, I have played a pivotal role in advancing the environmental and health research, innovation, and global engagement working at AstraZeneca (former Global Head of Environmental Protection and member of its Global Sustainability and UK Leadership Teams), for the European and International pharmaceutical industry trade associations (Efpia and IFPMA), for the Federation of European Chemical Industry Associations (CEFIC) and for the UKRIs Natural Environment Research Council (NERC).  I am a values-driven person that inspires others, strives for continual innovation and collaboration to deliver real-world impacts that help communities, businesses, and our planet. I have a career investigating the complex interdependencies between environment and human health, that has influenced business best practice and environmental policy at local, national, and international levels.  My research has been used in UKRI REF Impact case studies and I sat on the REF committee that assessed the impact of UKRI-NERC Facilities.

I have built collaborations with business, industry, government agencies and third sector organisations to enhance the uptake and application of research in environmental policy and business best practice.  These collaborative partnerships have been in several areas that relate to environmental and human health driving innovation and systems level thinking to tackle some of the critical challenges we are facing.  Research themes include:

  • Using metagenomic and machine learning approaches to assess the persistence, biodegradation and mobility of chemicals earlier in sustainable product development
  • Driving recognition of the importance of the environmental dimension of antimicrobial resistance (AMR) and assessing the effectiveness of proposed environmental stewardship and mitigation measures
  • Determining minimum selective concentrations for antibiotic resistence, co-selective agents and environmentally relevant mixtures
  • Managing the human and environmental health risks of drug manufacture and chemical production across value chains
  • Assessing the environmental sustainability of access to healthcare and medicines in low- and middle-income countries
  • The impact of climate change on public health, environmental pollution management
  • Integrating the climate and wider environmental footprint of medicinal products to help deliver patient centric net zero healthcare
  • Determining the overall persistence and environmental risks associated with next generation low global warming potential HFC/ HFA alternatives and their degradation products

I have a track record of securing research income from a variety of sources; examples include (i) >20M Euro funding from the European Commission via the Innovative Health Initiative (IHI) for the iPiE and Premier (initial Industry Consortium Leader) projects as well as other framework and horizon programmes, (ii) >£5M from the CEFIC Long-Range Research Programme (LRI) to investigate the persistence of chemicals in the environment, (iii) >40 PhD students (£3.6M) from UKRI-BBSRC Central Training Programme (CTP) for AstraZeneca, (iv) Sucessful track record in securing NERC Industrial CASE and BBSRC Industrial Partnership Awards (£>2M),(v) Innovate UK for animal welfare related work seeking to minimise fish testing (>£1M) and (vi) >£1M from Defra and the Environment Agency.

 

Employment History

At AstraZeneca I was accountable for updating the enterprise risk management team, senior executive team (SET), Board, and the market of emerging scientific and regulatory risks in the environmental sustainability area with well-defined and resourced mitigation plans. This included the physical (heat, humidity, flood, drought, fire, wind etc.) and transition (societal, market, regulatory, legal etc.) risks and opportunities that climate change posed the company and its entire value chain.  Disclosure of these climate-related risks and opportunities to TCFD is mandated by the Financial Conduct Authority.    I have significant Board-level leadership experience in AstraZeneca and other sectors (e.g. UKRI NERC Innovation Advisory Board, CEFIC Strategy and Innovation Group, Efpia Environmental Governance Group).  I also represented the wider pharmaceutical industry to the European Commission and European Medicines Agency.  Within AstraZeneca, I had Board and SET accountability for the strategic development and delivery of its environmental sustainability scorecard with key performance indicators for climate action, natural resource management (water stewardship, waste management and exploiting the circular (bio)economy), product sustainability (life cycle assessments, care pathway analysis, natural resource efficiency, green chemistry, regulatory environmental risk assessments, safe manufacturing discharges etc.), biodiversity and research.  I attended Full Board and relevant sub-committees providing written and verbal updates on strategic direction, performance against agreed targets, and emerging scientific, regulatory and disclosure risks.  I also supported the Chair of the Board, the CEO, CSO and Investor Relations at investor roadshows where sustainability issues were addressed.

Education/Academic qualification

PhD, Bacterial Metabolism of Nitrate Esters, Cardiff University

1 Oct 199130 Sept 1995

Award Date: 1 May 1996

BSc, Applied Sciences (focused on microbiology and biochemistry), University of Wolverhampton

1 Oct 198830 Jun 1991

Award Date: 30 Jun 1991

External positions

UK REACH Independent Scientific Expert, HEALTH AND SAFETY EXECUTIVE

1 Jan 2024 → …

REF Impact Committee, UKRI

1 Jan 202031 Dec 2020

Innovation Advisory Board, UKRI - Natural Environment Research Council

1 Jan 201731 Dec 2020

Chair of Environment Risk Assessment Working Group, European Federation of Pharmaceutical Industry Associations

1 Apr 201430 Jun 2023

Pharmaceuticals in the Environment Governance Group, European Federation of Pharmaceutical Industry Associations

1 Apr 201430 Jun 2023

Scientific Steering Committee, ECETOC

1 Jan 201031 Dec 2015

Strategy and Innovation Group, Federation of European Chemical Industry Associations (CEFIC)

1 Jan 201031 Dec 2015

Post-Genomics and Proteomics Science Coordinator, UKRI - Natural Environment Research Council

1 Jan 200431 Dec 2010

Environmental Genomics Science Coordinator, UKRI - Natural Environment Research Council

1 Jan 200231 Dec 2010

Honorary Clinical Professor, Department of Biological Sciences, Warwick University, UK

Honorary Professor of Practice, Department of Environmental Engineering, Newcastle University, UK

Keywords

  • GE Environmental Sciences
  • Ecosystems
  • Environmental toxicology
  • Environmental Analytical Chemistry
  • Pharmaceuticals
  • Antimicrobial Resistance
  • Risk and Resilience
  • Climate change
  • Policy
  • Bioengineering

Collaborations and top research areas from the last five years

Recent external collaboration on country/territory level. Dive into details by clicking on the dots or